Cargando…

The role of PD-1/PD-L1 axis in idiopathic pulmonary fibrosis: Friend or foe?

Idiopathic pulmonary fibrosis (IPF) is a devastating interstitial lung disease with a bleak prognosis. Mounting evidence suggests that IPF shares bio-molecular similarities with lung cancer. Given the deep understanding of the programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Aimin, Liu, Na, Wang, Jingjing, Zheng, Xiaoqiang, Ren, Mengdi, Zhang, Wei, Yao, Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760949/ https://www.ncbi.nlm.nih.gov/pubmed/36544757 http://dx.doi.org/10.3389/fimmu.2022.1022228

Ejemplares similares

PD-1/PD-L1 axis in organ fibrosis
por: Zhao, Youliang, et al.
Publicado: (2023)

Regulatory Immune Cells in Idiopathic Pulmonary Fibrosis: Friends or Foes?
por: van Geffen, Chiel, et al.
Publicado: (2021)

Macrophages: friend or foe in idiopathic pulmonary fibrosis?
por: Zhang, Lei, et al.
Publicado: (2018)

Targeting the PD-1/PD-L1 Axis in Human Vitiligo
por: Willemsen, Marcella, et al.
Publicado: (2020)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
por: Long, Yiru, et al.
Publicado: (2022)

Heme on Pulmonary Malaria: Friend or Foe?
por: Pádua, Tatiana Almeida, et al.
Publicado: (2020)

PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?
por: Simon, Sylvain, et al.
Publicado: (2017)

PD-L1 Expression in Patients with Idiopathic Pulmonary Fibrosis
por: Kronborg-White, Sissel, et al.
Publicado: (2021)

Autophagy in pulmonary fibrosis: friend or foe?
por: Hill, Charlotte, et al.
Publicado: (2021)

Regulatory Effect of PD1/PD-Ligand 1 (PD-L1) on Treg Cells in Patients with Idiopathic Pulmonary Fibrosis
por: Wang, Bing, et al.
Publicado: (2021)

Self-Eating: Friend or Foe? The Emerging Role of Autophagy in Idiopathic Pulmonary Fibrosis
por: Margaritopoulos, George A., et al.
Publicado: (2013)

Acute Exacerbation of Idiopathic Pulmonary Fibrosis With Pirfenidone and Nintedanib: A Friend or Foe
por: Kaushal, Mohit, et al.
Publicado: (2022)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

CRTH2 in Pulmonary Fibrosis: Friend or Foe?
por: He, Chao, et al.
Publicado: (2022)

Exercise sensitizes PD-1/PD-L1 immunotherapy as a hypoxia modulator in the tumor microenvironment of melanoma
por: Yan, Huiyu, et al.
Publicado: (2023)

The Schistosoma Granuloma: Friend or Foe?
por: Hams, Emily, et al.
Publicado: (2013)

Dendritic Cell Subsets in Type 1 Diabetes: Friend or Foe?
por: Morel, Penelope A.
Publicado: (2013)

Progress of research on PD-1/PD-L1 in leukemia
por: Cao, Huizhen, et al.
Publicado: (2023)

Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
por: Niu, Mengke, et al.
Publicado: (2022)

From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
por: Zhao, Xuan, et al.
Publicado: (2022)

Arginase in the Vascular Endothelium: Friend or Foe?
por: Lucas, Rudolf, et al.
Publicado: (2014)

ICOS Co-Stimulation: Friend or Foe?
por: Wikenheiser, Daniel J., et al.
Publicado: (2016)

Interleukin-33 in Malignancies: Friends or Foes?
por: Shen, Jia-Xin, et al.
Publicado: (2018)

Vaccination in Multiple Sclerosis: Friend or Foe?
por: Zrzavy, Tobias, et al.
Publicado: (2019)

Platelets in Neurodegenerative Conditions—Friend or Foe?
por: Leiter, Odette, et al.
Publicado: (2020)

Microglia in Multiple Sclerosis: Friend or Foe?
por: Guerrero, Brooke L., et al.
Publicado: (2020)

Expression of PD-1/PD-L1 axis in mediastinal lymph nodes and lung tissue of human and experimental lung fibrosis indicates a potential therapeutic target for idiopathic pulmonary fibrosis
por: Karampitsakos, Theodoros, et al.
Publicado: (2023)

Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
por: Jelinek, Tomas, et al.
Publicado: (2018)

Role of regulation of PD-1 and PD-L1 expression in sepsis
por: Zhang, Teng, et al.
Publicado: (2023)

Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer
por: Zhang, Yuedi, et al.
Publicado: (2022)

Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer
por: Jiang, Siqing, et al.
Publicado: (2022)

Early Activation of Myeloid-Derived Suppressor Cells Participate in Sepsis-Induced Immune Suppression via PD-L1/PD-1 Axis
por: Ruan, Wei-Shuyi, et al.
Publicado: (2020)

The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
por: Tang, Qing, et al.
Publicado: (2022)

Lung cancer patients with chronic obstructive pulmonary disease benefit from anti-PD-1/PD-L1 therapy
por: Lin, Mao, et al.
Publicado: (2022)

Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression
por: Pu, Yunzhou, et al.
Publicado: (2022)

Exosomes and Immune Response in Cancer: Friends or Foes?
por: Barros, Francisco M., et al.
Publicado: (2018)

Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend
por: Locy, Hanne, et al.
Publicado: (2018)

Tim-4 in Health and Disease: Friend or Foe?
por: Liu, Wen, et al.
Publicado: (2020)

Cytomegaloviruses and Macrophages—Friends and Foes From Early on?
por: Baasch, Sebastian, et al.
Publicado: (2020)

Role of Lactate in Inflammatory Processes: Friend or Foe
por: Manosalva, Carolina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_alv6bnthe45ubo2n06icpvbj6n